Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Corneal Dystrophies, Hereditary Clear all
Completed Phase 2 Interventional

TTHX1114(NM141) in Combination With DWEK/DSO

NCT04676737
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
Interventions
TTHX1114(NM141)
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Completed No phase listed Observational

Air Optix® Night and Day® Aqua Therapeutic Wear

NCT05956535
View directory record Official record
Conditions
Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy
Interventions
Lotrafilcon A contact lenses, Balafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Delray Beach, Florida • St Louis, Missouri • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05376176
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 9, 2026, 1:43 PM EDT
Completed No phase listed Observational

Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases

NCT00357435
View directory record Official record
Conditions
Corneal Dystrophies, Hereditary, Corneal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 9, 2026, 1:43 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

NCT07750678
View directory record Official record
Conditions
Hereditary Corneal Dystrophy, Corneal Abnormality, Corneal Dystrophies, Corneal Dystrophies, Hereditary
Interventions
GEB-101 Injection
Genetic
Lead sponsor
GenEditBio Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Not listed Phase 2 Interventional

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

NCT03813056
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty
Drug · Procedure
Lead sponsor
Michael D. Straiko, MD
Other
Eligibility
30 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy

NCT00346853
View directory record Official record
Conditions
Macular Dystrophy, Corneal
Interventions
4-Methylpyrazole, saline
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting No phase listed Observational

OCT in Fuchs' Dystrophy

NCT04258787
View directory record Official record
Conditions
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

NCT00624221
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy, Corneal Edema
Interventions
Descemet's stripping endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Netarsudil Ophthalmic Solution, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 9, 2026, 1:43 PM EDT
Terminated No phase listed Observational

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

NCT04527523
View directory record Official record
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 9, 2026, 1:43 PM EDT
Terminated Not applicable Interventional

Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy

NCT06202651
View directory record Official record
Conditions
Granular Dystrophy, Corneal
Interventions
Nd:YAG Laser
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Combined Cataract Surgery and Planned Descemetorhexis

NCT02206594
View directory record Official record
Conditions
Fuchs' Corneal Dystrophy, Cataract
Interventions
Descemetorhexis
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07729137
View directory record Official record
Conditions
Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions
150K cells, 500K cells, Placebo
Biological · Procedure
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Torrance, California • Largo, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05826353
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting Phase 4 Interventional

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

NCT03249337
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Drug
Lead sponsor
Marian Macsai, MD
Other
Eligibility
18 Years to 91 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 9, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

NCT06261346
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions
Endothelial keratoplasty, PRGF
Procedure · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Miami, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PIONEER: Intraoperative and Perioperative OCT Study

NCT02423161
View directory record Official record
Conditions
Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 9, 2026, 1:43 PM EDT
Terminated No phase listed Observational

The Natural History of Mucolipidosis Type IV

NCT01067742
View directory record Official record
Conditions
Mucolipidosis Type IV
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Year to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 9, 2026, 1:43 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

NCT03971357
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 9, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 9, 2026, 1:43 PM EDT